Related Experiment Video
Updated: Apr 28, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
[Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation
1Dept. of Clinical Oncology, National Hospital Organization Kinki-chuo Chest Medical Center.
Abstract:
Somatic activating mutations such as a deletion in exon 19 or the missense mutation L858R in the tyrosine kinase domain of the epidermal growth factor receptor(EGFR)are important mediators of cancer cell oncogenesis, proliferation, and survival. In the last decade, two EGFR target agents have significantly contributed to the understanding of non-small cell lung cancer (NSCLC). Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. Although these reversible, small, molecular target agents provide a significant response and survival benefit, all responders eventually acquire resistance. Although various mechanisms of resistance have been identified, nearly 3 0% of patients who acquire resistance to EGFR-TKIs have an unknown mechanism of resistance. Approximately half the patients with EGFR-mutated NSCLC who develop acquired resistance to these molecular target agents have a secondary mutation T790M in the threonine gatekeeper residue that coexists with a primary EGFR activating mutation. The strategy for overcoming acquired resistance to first-generation EGFR-TKIs is a major clinical concept. Afatinib is a second-generation EGFR-targeting agent and an irreversible pan-HER inhibitor. It may improve survival further and help in potentially overcoming resistance to first-generation EGFR-TKIs in EGFR-mutated NSCLC. In patients harboring activating EGFR mutations, certain treatments could be suggested for subsequent therapy after failure of first-generation EGFR-TKIs. This review discusses novel therapeutic strategies for activating EGFR-mutated, advanced NSCLC after failure of first-generation EGFR-TKIs.
Insights
Activating mutations in epidermal growth factor receptor (EGFR) drive non-small cell lung cancer (NSCLC). First-generation EGFR inhibitors like gefitinib are effective but resistance develops, often due to T790M mutations. Second-generation inhibitors like afatinib offer potential to overcome this resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Somatic activating mutations in the epidermal growth factor receptor (EGFR), such as exon 19 deletions or the L858R missense mutation, are key drivers of non-small cell lung cancer (NSCLC) oncogenesis, proliferation, and survival.
- First-generation EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, have shown significant efficacy in EGFR-mutated NSCLC, improving response rates and survival.
- Acquired resistance to these TKIs is inevitable, with approximately half of resistant cases developing a secondary T790M mutation, complicating treatment strategies.
Purpose of the Study:
- To review novel therapeutic strategies for advanced EGFR-mutated NSCLC following failure of first-generation EGFR-TKIs.
- To discuss the role of second-generation EGFR inhibitors, such as afatinib, in overcoming resistance mechanisms.
- To explore treatment options for patients with EGFR-mutated NSCLC who develop acquired resistance to initial targeted therapies.
Main Methods:
- Literature review of studies on EGFR mutations in NSCLC.
- Analysis of clinical data regarding the efficacy and resistance patterns of EGFR-TKIs.
- Examination of the mechanisms of resistance to first-generation EGFR-TKIs, including the T790M mutation.
- Evaluation of second-generation EGFR inhibitors and other novel therapeutic approaches.
Main Results:
- First-generation EGFR-TKIs provide significant benefits but are associated with acquired resistance.
- The T790M mutation is a major mechanism of acquired resistance to gefitinib and erlotinib.
- Second-generation inhibitors like afatinib demonstrate potential in overcoming resistance and improving outcomes in EGFR-mutated NSCLC.
Conclusions:
- Effective management of EGFR-mutated NSCLC requires strategies to overcome acquired resistance to first-generation TKIs.
- Afatinib and other novel agents represent promising therapeutic options for patients who progress on initial EGFR-targeted therapy.
- Further research into resistance mechanisms and the development of next-generation inhibitors is crucial for improving long-term survival in NSCLC.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...